

# Oncogene Inhibitor Market Analysis 2025 – Insights For Long-Term Investment & Planning

*The Business Research Company's  
Oncogene Inhibitor Global Market  
Report 2025 – Market Size, Trends, And  
Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED  
KINGDOM, July 3, 2025

/EINPresswire.com/ -- Save 30% On All  
Global Market Reports With Code

ONLINE30 – Stay Informed On Tariff Changes, Macroeconomic Trends, and much more.



The Business  
Research Company

Oncogene Inhibitor Global Market Report 2025

What Is The Anticipated Growth Rate And Market Size Of The Global Oncogene Inhibitor Market?

“

Save 30% On All Global  
Market Reports With Code  
ONLINE30 – Stay Informed  
On Tariff Changes,  
Macroeconomic Trends, and  
much more.”

*The Business Research  
Company*

The [oncogene inhibitor market](#) has grown robustly in recent years. The market value was \$39.68 billion in 2024, and it will climb to a staggering \$43.27 billion in 2025, reflecting a compound annual growth rate CAGR of 9.0%. Factors contributing to this growth in the historic period include a rise in resistance mechanism research, the rise of targeted therapies, growing focus on research for lung cancer treatments, increased investment in kras and myc inhibitors, and an influx of funding and grants.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24635&type=smp>

What Are The Key Growth Drivers Of The Oncogene Inhibitor Market Going Forward?

The oncogene inhibitor market size is projected to see strong growth in the next few years. The value is expected to rise to \$60.36 billion in 2029, exhibiting a CAGR of 8.7%. The growth in the forecast period can be credited to increasing investments in healthcare, a growing emphasis on tumor-agnostic therapies, the rising adoption of targeted therapies, a favorable regulatory and reimbursement landscape, and the ongoing development of personalized therapy and companion diagnostics. Apart from these aspects, the forecast period will witness some major trends such as next-generation KRAS inhibitors, AI-driven drug discovery, real-time liquid biopsy

integration, modulation of the tumor microenvironment, and targeted nanoparticle drug delivery.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/oncogene-inhibitor-global-market-report>

### What Is Driving The Growth Of The Oncogene Inhibitor Market Market?

An increase in the prevalence of cancer is expected to fuel the development of the oncogene inhibitor market going forward. Oncogene inhibitors play a vital role in cancer treatment by targeting and blocking specific genes that precipitate cancer cell growth, thereby slowing or stopping tumor development and progression. According to a 2024 report by Cancer Research UK, the average annual number of new melanoma skin cancer cases in the UK will rise from approximately 20,800 in 2023-2025 to around 26,500 in 2038-2040. This increase in the prevalence of cancer further propels the growth of the oncogene inhibitor market.

### Who Are The Key Industry Players And What Are The Emerging Trends Of The Oncogene Inhibitor Market?

Major companies operating in the oncogene inhibitor market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mirati Therapeutics Inc., AstraZeneca PLC, Incyte Corporation, Blueprint Medicines Corporation, Astex Pharmaceuticals Inc., G1 Therapeutics Inc., Nurix Therapeutics Inc., GenFleet Therapeutics Co Ltd., and Relay Therapeutics Inc.

These companies are focusing on developing innovative treatment options, such as novel functional genomic approaches, to enhance the precision and efficacy of cancer treatments. Specifically, in May 2024, Delphia Therapeutics introduced a novel approach called activation lethality to exploit cancer's vulnerability to oncogene overactivation. This innovative methodology selectively kills cancer cells that rely on this overactivation for survival, while sparing healthy cells.

### How Is The [Oncogene Inhibitor Market Segmented](#)?

The oncogene inhibitor market could be segmented into several categories:

- 1 By Type: Oral, Injection
- 2 By Drug Class: Small Molecule Drugs, Biologics, Combination Therapies
- 3 By Indication: Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreas Cancer, Other Indications
- 4 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- 5 By End-Users: Hospitals, Specialty Clinics, Other End-Users

Subsegments include:

- 1 By Oral Oncogene Inhibitors: Small Molecule Inhibitors, Targeted Therapy Pills, Tyrosine Kinase

Inhibitors TKIs

2 By Injection Oncogene Inhibitors: Monoclonal Antibodies mAbs, Peptide Receptor Radioligand Therapy PRRT, Small Molecule Inhibitors Injectable, Gene Therapy Injections

What Are The Regional Insights Into The Oncogene Inhibitor Market?

North America emerged as the largest region in the oncogene inhibitor market in 2024, while Asia-Pacific is expected to be the fastest-growing region in the next few years. The regions covered in the oncogene inhibitor market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Oncolytic Virus Therapy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report>

Antiglaucoma Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report>

Kinase Inhibitors Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report>

### [About The Business Research Company](#)

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_fl0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/827961882>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.